肾脏类器官作为一种前沿的三维体外模型,在2025年迎来了爆发式发展。通过梳理今年发表的数十篇高质量文献,华津生物为您总结肾脏类器官研究的最新进展、核心应用与未来挑战。
传统肾脏类器官缺乏空间结构和完整功能。今年,南加州大学李中伟教授团队开发出迄今最高阶的肾脏类器官,首次实现了肾单位与集合系统的空间自组装,显著提升了细胞复杂性和成熟度,并在移植后表现出功能活性。
Uusi-Rauva et al. 建立了一种微孔板高通量培养系统,结合多元统计分析,显著提高了类器官形态的一致性与可重复性,为大规模药物筛选铺平道路。
Alport综合征:Saei et al. 利用患者来源类器官验证了ASO疗法对COL4A5剪接突变的有效性。
ADPKD(多囊肾病):多个研究通过基因编辑构建PKD1/2突变类器官,成功模拟囊肿形成,并用于药物筛选(如托伐普坦、新型cAMP抑制剂)。
APOL1介导肾病:Song et al. 发现APOL1风险变异导致足细胞代谢重编程与线粒体功能障碍。
缺血/炎症模型:Li et al. 结合缺氧与IL-1β诱导肾纤维化,并观察到小管再生潜力。
药物肾毒性:类器官广泛用于评估顺铂、庆大霉素、马兜铃酸等药物的肾小管毒性,并揭示其通过氧化应激、凋亡等途径损伤细胞。
Minakawa et al. 利用缺氧肾脏类器官模型,发现达格列净通过改善线粒体应激、减少ROS积累与细胞凋亡,缓解缺氧诱导的小管损伤与纤维化。
FTO抑制剂:Zhang et al. 发现抑制FTO可通过下调ACSL4和TGFBI,减轻铁死亡与肾纤维化。
抗血小板治疗:Rustiasari et al. 揭示血小板通过TGF-β1信号促进小管上皮间质转化与纤维化,提示抗血小板药物或具肾脏保护潜力。
PHLOWER 等新型算法能够利用多模态单细胞数据推断复杂分支分化轨迹,助力识别类器官中的“脱靶”细胞并预测转录调控因子。
GelMA水凝胶:通过调节硬度(模拟成人肾脏刚度)可显著促进足细胞成熟,并影响TGF-β诱导的纤维化反应。
肾脏微环境图谱倡议:Koldenhof et al. 呼吁建立分段特异性细胞外基质与力学特性图谱,以指导更生理化的类器官构建。
Garreta et al. 首次报道了人源肾脏类器官在离体猪肾机器灌注系统中的移植与存活,并观察到初步的体内嵌合,为未来细胞治疗奠定了基础。
肾细胞癌(RCC)等肿瘤类器官能够保留患者肿瘤的组织学与分子特征,用于个性化药物敏感性测试与免疫治疗预测。
尽管进展显著,肾脏类器官仍面临以下挑战:
成熟度不足:类器官细胞仍处于胎儿样状态,缺乏成人肾脏功能。
血管化与神经化缺失:限制营养供应、信号交流与功能整合。
标准化与可重复性:不同实验室、细胞系、培养条件之间存在显著差异。
结构完整性:仍难以实现肾单位与集合系统的完整连接及尿液引流功能。
未来,随着生物工程、多组学整合、人工智能等技术的进一步融合,肾脏类器官有望在疾病建模、药物筛选、毒性评估乃至再生医学中发挥更加关键的作用。
1. Huang, Biao et al. “Spatially patterned kidney assembloids recapitulate progenitor self-assembly and enable high-fidelity in vivo disease modeling.” Cell stem cell vol. 32,10 (2025): 1614-1633.e13
2. Uusi-Rauva, Kristiina et al. “Parsing Glomerular and Tubular Structure Variability in High-Throughput Kidney Organoid Culture.” Methods and protocols vol. 8,5 125. 19 Oct. 2025
3. Saei, Hassan et al. “Splice modulation of COL4A5 reinstates collagen IV assembly in an organoid model of Alport syndrome.” JCI insight, e194759. 18 Dec. 2025
4. Scarlat, Alexandru et al. “PKD1 mutation perturbs morphogenesis in tubular epithelial organoids derived from human pluripotent stem cells.” Scientific reports vol. 15,1 10375. 26 Mar. 2025
5. Song, Heein et al. “APOL1 risk variants induce metabolic reprogramming of podocytes in patient-derived kidney organoids.” Stem cell reports vol. 20,10 (2025): 102650
6. Suzuki, Takefumi et al. “iPSC-based drug discovery identified the Hippo signaling pathway as a therapeutic target in the fibrosis of NPHP1-deficient nephronophthisis.” Stem cell research & therapy vol. 16,1 489. 19 Sep. 2025
7. Xi, Yue, and Wei Song. “Kidney organoids in translational research: disease modeling, drug discovery, and unresolved challenges.” Cell and tissue research vol. 402,3 (2025): 303-312
8. Minakawa, Akihiro et al. “Dapagliflozin mitigates hypoxia-induced metabolic stress, kidney tubular cell death and fibrosis.” bioRxiv : the preprint server for biology 2025.12.13.693777. 16 Dec. 2025
9. Zhang, Dalin et al. “FTO inhibition attenuates renal fibrosis by downregulating ferroptosis activator ACSL4 and profibrotic factor TGFBI.” iScience vol. 28,10 113515. 7 Sep. 2025
10. Rustiasari, Ukhti Jamil et al. “Platelets induce epithelial to mesenchymal transition in renal proximal tubular epithelial cells through TGF-β signaling pathway.” Molecular medicine (Cambridge, Mass.) vol. 31,1 318. 29 Oct. 2025
11. Cheng, Mingbo et al. “PHLOWER leverages single-cell multimodal data to infer complex, multi-branching cell differentiation trajectories.” Nature methods vol. 22,11 (2025): 2328-2336
12. Clerkin, Shane et al. “Tuneable gelatin methacryloyl (GelMA) hydrogels for the directed specification of renal cell types for hiPSC-derived kidney organoid maturation.” Biomaterials vol. 322 (2025): 123349
13. Koldenhof, Jim et al. “How a kidney microenvironment atlas can advance kidney tissue engineering.” Trends in biotechnology, S0167-7799(25)00359-2. 2 Oct. 2025
14. Garreta, Elena et al. “Systematic production of human kidney organoids for transplantation in porcine kidneys during ex vivo machine perfusion.” Nature biomedical engineering, 10.1038/s41551-025-01542-1. 31 Oct. 2025
15. Gao, Jian et al. “Renal cell carcinoma organoids for precision medicine: bridging the gap between models and patients.” Journal of translational medicine vol. 23,1 1152. 21 Oct. 2025
公司地址
深圳
广东省深圳市龙华区观澜银星智界2期A座11楼
广州
广东省广州和盛广场
武汉
湖北武汉光谷生物城
联系电话
商务支持
17276665437(李先生)
技术支持
18843183823(田先生)